AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0039
Drug name and formulations:		Enstilar® cutaneous foam (calcipotriol 50mcg/g & betamethasone 0.5mg/g)
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Safety concerns: flammable risk as per MHRA alert (excipients include liquid paraffin, butane)
Clinical effectiveness	*Established licensed product*	Benefit over comparator was demonstrated in PSO-ABLE study; Enstilar® cutaneous foam achieved higher treatment success rates then Dovobet® gel.
Strength of evidence		Moderate to weak- small studies over short periods of time
Cost effectiveness or resource impact	*£*	Cost neutral against comparator.
Place of therapy relative to available treatments	*1/2nd tier*	Alternative option for patients- first line.
National guidance and priorities	*NICE, MTRAC*	SMC accepted. PCDS guidelines recommend combination calcipotriol/betamethasone formulations first line in chronic plaque psoriasis.
Local health priorities	*CCG views*	CCGs support use.
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN, add to current formulary. Remove ointment formulation in 6 months (1 June 2017) as suggested by applicant, unless hear from other dermatologists to contrary.
Implementation requirements:	
Implementation monitoring:	